- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02028975
Search for Biological Markers of Orosensory Perception of Fatty Acids in Healthy Subjects and Possible Modifications in Patients With Type 2 Diabetes and in Obese Non-diabetic Patients.
Animal studies have shown that stimulation of the lingual lipid-receptor, CD 36, is accompanied by the rapid secretion of hormones in the digestive tract (incretines). We aim to determine in healthy humans whether the orosensory perception of fatty acids is followed by a modification in plasma levels of digestive tract hormones (cholecystokinin, GIP, GLP-1, secretin, pancreatic peptide, peptide YY, insulin) and metabolic markers from adipose tissue (leptin, ghrelin, adiponectin).
We also aim to determine whether the hormonal response induced by orosensory stimulation by lipids is modified:
- in patients with type 2 diabetes
- in obese non-diabetic patients We expect to show an increase in biological markers biological, and more particularly in certain digestive hormones such as Pancreatic polypeptide, GIP, GLP-1…after stimulation of the lingual lipid receptor, CD36. We will also determine whether or not this response is modified in patients with type 2 diabetes and in obese non-diabetic patients.
We also wish to measure the subjects' gustatory detection threshold for a fatty acid (linoleic acid), and to determine whether there is a relationship between the orosensory perception threshold for linoleic acid and the physiological status of the subjects. In order to achieve this, the thresholds for healthy subjects will be compared with thresholds for obese and diabetic subjects. Expected results: the threshold of detection for linoleic acid in healthy subjects will be lower than that in obese or diabetic patients.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Bruno VERGES
- Phone Number: +33 3 80 29 34 53
- Email: bruno.verges@chu-dijon.fr
Study Locations
-
-
-
Dijon, France, 21079
- Recruiting
- CHU Dijon
-
Contact:
- Isabelle ROBIN
- Phone Number: +33 3 80 29 33 32
- Email: isabelle.simoneau-robin@chu-dijon.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- persons who have provided written consent
- Healthy volunteers:
- Men > 18 years
- 19 <BMI < 25 kg.m-2
- Fasting triglyceridemia < 1.50 g/l
- Fasting glycemia < 1.10 g/l
- Without regular medical treatment
- Patients with type-2 diabetes:
- Men >18 years
- type 2 diabetes (fasting glycemia > 7 mmol/l at the diagnosis) treated with diet or diet + oral antidiabetics (metformin, and/or insulinsecretion agents [hypoglycemic sulphonamides, or glinides] and/or glitazones and/or acarbose)
- Stable oral antidiabetic treatment for 3 months
- Obese non-diabetic patients:
- Men > 18 years
- BMI 30 kg.m-2
- Fasting glycemia < 1.10 g/l
- HbA1c < 6.0%
- Absence of treatment with hypoglycemic agents (including benfluorex)
- Absence of medical treatment for obesity
- Absence of a history of surgery for obesity (band, by-pass) or gastric stimulator (type Tantalus)
Exclusion Criteria:
- Persons not covered by the national health insurance
- Smokers, or smoking cessation within the 3 months preceding inclusion
- Persons with eating disorders:
- Severe digestive disease (enteropathy with absorption disorders, inflammatory digestive disease)
- Pancreatic insufficiency
- History of pancreas surgery
- Type 1 diabetes
- Renal insufficiency
- Hepatic insufficiency
- Treatment with proton pump inhibitors, insulin, GLP-1 analogues, DPP-4 inhibitors
Study Plan
How is the study designed?
Design Details
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Patients with type 2 diabetes
|
|
Other: Healthy volunteers
|
|
Other: Obese patients without diabetes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma levels of biological markers of orosensorielle perception fatty acids
Time Frame: Change from baseline at 15 days
|
Change from baseline at 15 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Measure the detection threshold for linoleic acid
Time Frame: baselines
|
baselines
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Besnard P, Christensen JE, Bernard A, Simoneau-Robin I, Collet X, Verges B, Burcelin R. Identification of an oral microbiota signature associated with an impaired orosensory perception of lipids in insulin-resistant patients. Acta Diabetol. 2020 Dec;57(12):1445-1451. doi: 10.1007/s00592-020-01567-9. Epub 2020 Jul 16.
- Chevrot M, Passilly-Degrace P, Ancel D, Bernard A, Enderli G, Gomes M, Robin I, Issanchou S, Verges B, Nicklaus S, Besnard P. Obesity interferes with the orosensory detection of long-chain fatty acids in humans. Am J Clin Nutr. 2014 May;99(5):975-83. doi: 10.3945/ajcn.113.077198. Epub 2014 Feb 12.
Study record dates
Study Major Dates
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VERGES 2009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes or Obesity Without Diabetes
-
University of ZambiaUniversity Teaching Hospital, Lusaka, ZambiaNot yet recruitingDiabetes Mellitus Type 2 Without Complication
-
Centro Universitario de Ciencias de la Salud, MexicoActive, not recruitingDiabetes Mellitus Type 2 Without ComplicationMexico
-
Seoul National University HospitalMerck Sharp & Dohme LLCUnknownType 2 Diabetes Mellitus Without Insulin TreatmentKorea, Republic of
-
Lille Catholic UniversityCentre Hospitalier ArrasRecruitingObesity Without Type 2 Diabetes, With BMI>30France
-
Heidelberg Engineering GmbHCompletedNormal Eyes of Subjects Without Diabetes Mellitus | Subjects With Diabetes Mellitus Type 2 Without Coexisting DPN | Subjects With Diabetes Mellitus Type 2 With Coexisting Early to Moderate DPN
-
Rio de Janeiro State UniversityCompletedOverweight | Pre Diabetes | Diabetes Mellitus Type 2 Without Complication
-
MedtronicNeuroCompletedSevere to Morbid Obesity and Type 2 DiabetesUnited States
-
Des Moines UniversityPenn State University; Indiana University; EpiGenTek, LLCActive, not recruitingIncident Type 2 Diabetes | Incident ObesityUnited States
-
The Cleveland ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Enrolling by invitationObesity | Type 2 Diabetes MellitusUnited States
-
Mayo ClinicCompletedObesity | Type 2 Diabetes MellitusUnited States
Clinical Trials on Measure the threshold of detection for linoleic acid
-
Hackensack Meridian HealthUppsala University, Sweden (Department of Immunology, Genetics and Pathology)Suspended
-
Universitaire Ziekenhuizen KU LeuvenSanten OyCompleted
-
International Agency for Research on CancerRegional Cancer Centre, Trivandrum, IndiaCompletedBreast Cancer
-
De Soysa Hospital for WomenClinical Innovations, LLCUnknownPremature Rupture of MembranesSri Lanka
-
University Hospital Inselspital, BerneAmniSure International LLCCompletedPreterm Birth | Preterm LabourSwitzerland
-
Clinical Innovations, LLCUnknown
-
CHU de ReimsUnknownPancreatic ResectionFrance
-
Assistance Publique - Hôpitaux de ParisRecruitingSensorineural Hearing LossFrance
-
Pathway GenomicsCompletedNeoplasms | MutationUnited States
-
Institut National de la Santé Et de la Recherche...Completed